By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...

This was the stock's second consecutive day of gains.

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...

MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, ...